OBJECTIVE: To examine the relative importance of tumor necrosis factor receptor I (TNFRI) signaling in the hematopoietic tissue compartment in the progression of collagen-induced arthritis (CIA), a model of rheumatoid arthritis (RA). METHODS: DBA/1 mice were administered a lethal radiation dose and were then rescued with bone marrow derived from either DBA/1 or TNFRI(-/-) mice. CIA was then induced, and disease progression was characterized. RESULTS: Surprisingly, mice with CIA that received TNFRI(-/-) donor marrow developed increased disease severity as compared with control mice with CIA. This could not be attributed to an increased primary response to collagen or to the contribution of a non-DBA genetic background. In mice that received TNFRI(-/-) bone marrow, histologic markers of advanced disease were evident shortly after initiation of the immune response to collagen and long before clinical evidence of disease. Serum TNFalpha was undetectable, whereas serum interleukin-12 p40 levels were increased, at the end point of the study in mice that received TNFRI(-/-) bone marrow. CONCLUSION: These data raise the intriguing possibility of the existence of an antiinflammatory, TNFRI-mediated circuit in the hematopoietic compartment. This circuit bears a resemblance to the switch in TNFalpha function that has been observed during the resolution of bacterial infections. These data suggest that TNFRI-mediated signals in the radioresistant tissues contribute to disease progression, whereas TNFRI-mediated signals in the radiosensitive tissues can contribute to protection from disease. We thus put forward the hypothesis that the degree of response to TNFalpha blockade in RA is dependent in part on the relative genetic strengths of these 2 pathways.
OBJECTIVE: To examine the relative importance of tumor necrosis factor receptor I (TNFRI) signaling in the hematopoietic tissue compartment in the progression of collagen-induced arthritis (CIA), a model of rheumatoid arthritis (RA). METHODS:DBA/1 mice were administered a lethal radiation dose and were then rescued with bone marrow derived from either DBA/1 or TNFRI(-/-) mice. CIA was then induced, and disease progression was characterized. RESULTS: Surprisingly, mice with CIA that received TNFRI(-/-) donor marrow developed increased disease severity as compared with control mice with CIA. This could not be attributed to an increased primary response to collagen or to the contribution of a non-DBA genetic background. In mice that received TNFRI(-/-) bone marrow, histologic markers of advanced disease were evident shortly after initiation of the immune response to collagen and long before clinical evidence of disease. Serum TNFalpha was undetectable, whereas serum interleukin-12 p40 levels were increased, at the end point of the study in mice that received TNFRI(-/-) bone marrow. CONCLUSION: These data raise the intriguing possibility of the existence of an antiinflammatory, TNFRI-mediated circuit in the hematopoietic compartment. This circuit bears a resemblance to the switch in TNFalpha function that has been observed during the resolution of bacterial infections. These data suggest that TNFRI-mediated signals in the radioresistant tissues contribute to disease progression, whereas TNFRI-mediated signals in the radiosensitive tissues can contribute to protection from disease. We thus put forward the hypothesis that the degree of response to TNFalpha blockade in RA is dependent in part on the relative genetic strengths of these 2 pathways.
Authors: Y Tada; A Ho; S Koarada; F Morito; O Ushiyama; N Suzuki; Y Kikuchi; A Ohta; T W Mak; K Nagasawa Journal: Clin Immunol Date: 2001-06 Impact factor: 3.969
Authors: Nirmal K Banda; Andrea Vondracek; Damian Kraus; Charles A Dinarello; Soo-Hyun Kim; Alison Bendele; Giorgio Senaldi; William P Arend Journal: J Immunol Date: 2003-02-15 Impact factor: 5.422
Authors: Jennifer H Anolik; Rajan Ravikumar; Jennifer Barnard; Teresa Owen; Anthony Almudevar; Eric C B Milner; Chase H Miller; Paul O Dutcher; James A Hadley; Iñaki Sanz Journal: J Immunol Date: 2008-01-15 Impact factor: 5.422
Authors: Craig A Murphy; Claire L Langrish; Yi Chen; Wendy Blumenschein; Terrill McClanahan; Robert A Kastelein; Jonathon D Sedgwick; Daniel J Cua Journal: J Exp Med Date: 2003-12-08 Impact factor: 14.307
Authors: Onno J Arntz; Jeroen Geurts; Sharon Veenbergen; Miranda B Bennink; Ben T van den Brand; Shahla Abdollahi-Roodsaz; Wim B van den Berg; Fons A van de Loo Journal: Arthritis Res Ther Date: 2010-04-06 Impact factor: 5.156
Authors: Andrea Constanza Mayordomo; Juan Eduardo Silva; Carolina Virginia Gorlino; José Luis Arias; Walter Berón; María Silvia Di Genaro Journal: PLoS One Date: 2018-03-01 Impact factor: 3.240